Combination Estrogen–Progestin Contraceptives and Body Weight: Systematic Review of Randomized Controlled Trials

OBJECTIVE: Many women and clinicians believe that combination estrogen–progestin contraceptive use can lead to weight gain. This concern can deter women from starting hormonal contraception or lead to premature quitting. This review evaluated the association between combination contraceptive use and change in body weight. DATA SOURCES: The computerized databases CENTRAL, MEDLINE, EMBASE, Popline, and LILACS (from their inception to 2002) were used to conduct this review. Known investigators and manufacturers were contacted for information about other trials not discovered in the database search. METHODS OF STUDY SELECTION: All English-language, randomized controlled trials measuring weight change that were at least 3 treatment cycles in duration and that compared a combination contraceptive to a placebo or to a combination contraceptive that differed in drug, dosage, regimen, or study length were eligible for inclusion. Of the 570 reports of randomized controlled trials of eligible interventions that were identified, 42 trials were included in the systematic review. TABULATION, INTEGRATION, AND RESULTS: Two reviewers independently abstracted data from the eligible trials using a standard form. Depending on the data available, the weighted mean difference using a fixed effect model with 95% confidence intervals was calculated for the mean change in weight between baseline and posttreatment measurements or the Peto odds ratio with 95% confidence intervals was calculated by using the proportion of women who gained or lost more than a specified amount of weight. The 3 placebo-controlled, randomized trials did not find evidence supporting a causal association between combination oral contraceptives or a combination skin patch and weight gain. Most comparisons from the 40 trials that compared 2 or more combination contraceptives showed no substantial difference in weight. In addition, discontinuation of combination contraceptives because of weight gain did not differ between groups when this factor was studied. CONCLUSION: Available evidence is insufficient to determine the effect of combination contraceptives on weight, but no large effect is evident.

[1]  A. Worsley.  A prospective study of the effects of the progestagen content of oral contraceptives on measures of affect, automatization, and perceptual restructuring ability , 2004, Psychopharmacology.

[2]  I. Wiegratz,et al.  Effect of dienogest-containing oral contraceptives on lipid metabolism. , 2002, Contraception.

[3]  Kenneth F Schulz,et al.  Blinding in randomised trials: hiding who got what , 2002, The Lancet.

[4]  Kenneth F Schulz,et al.  Allocation concealment in randomised trials: defending against deciphering , 2002, The Lancet.

[5]  Peter Jüni,et al.  Direction and impact of language bias in meta-analyses of controlled trials: empirical study. , 2002, International journal of epidemiology.

[6]  L. Miller,et al.  Menstrual Reduction With Extended Use of Combination Oral Contraceptive Pills: Randomized Controlled Trial , 2001, Obstetrics and gynecology.

[7]  C. Gerlinger,et al.  Open, multicenter comparison of efficacy, cycle control, and tolerability of a 23-day oral contraceptive regimen with 20 μg ethinyl estradiol and 75 μg gestodene and a 21-day regimen with 20 μg ethinyl estradiol and 150 μg desogestrel , 2001 .

[8]  C. Gerlinger,et al.  Multicenter, comparative study of cycle control, efficacy and tolerability of two low-dose oral contraceptives containing 20 μg ethinylestradiol/100 μg levonorgestrel and 20 μg ethinylestradiol/500 μg norethisterone , 2001 .

[9]  F. Laporte,et al.  Effects of two low-dose oral contraceptives containing ethinylestradiol and either desogestrel or levonorgestrel on serum lipids and lipoproteins with particular regard to LDL size. , 2001, Contraception.

[10]  J. DiGiovanna,et al.  Weight change and adverse event incidence with a low-dose oral contraceptive: two randomized, placebo-controlled trials. , 2001, Contraception.

[11]  C. Gerlinger,et al.  Multicenter, comparative study of cycle control, efficacy and tolerability of two low-dose oral contraceptives containing 20 microg ethinylestradiol/100 microg levonorgestrel and 20 microg ethinylestradiol/500 microg norethisterone. , 2001, Contraception.

[12]  W. Chandler,et al.  Comparison of the lipoprotein, carbohydrate, and hemostatic effects of phasic oral contraceptives containing desogestrel or levonorgestrel. , 2001, Contraception.

[13]  C. Gerlinger,et al.  Open, multicenter comparison of efficacy, cycle control, and tolerability of a 23-day oral contraceptive regimen with 20 microg ethinyl estradiol and 75 microg gestodene and a 21-day regimen with 20 microg ethinyl estradiol and 150 microg desogestrel. , 2001, Contraception.

[14]  A R Jadad,et al.  What contributions do languages other than English make on the results of meta-analyses? , 2000, Journal of clinical epidemiology.

[15]  R. Troiano,et al.  Changes in the distribution of body mass index of adults and children in the US population , 2000, International Journal of Obesity.

[16]  A. Kaunitz.  Efficacy, cycle control, and safety of two triphasic oral contraceptives: Cyclessa (desogestrel/ethinyl estradiol) and ortho-Novum 7/7/7 (norethindrone/ethinyl estradiol): a randomized clinical trial. , 2000, Contraception.

[17]  K. Thomas,et al.  Inhibition of ovulation by a novel progestogen (drospirenone) alone or in combination with ethinylestradiol , 2000, The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception.

[18]  W. Oelkers,et al.  Effect of an oral contraceptive containing drospirenone on the renin-angiotensin-aldosterone system in healthy female volunteers , 2000, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[19]  C. Gerlinger,et al.  Comparison of efficacy, cycle control, and tolerability of two low-dose oral contraceptives in a multicenter clinical study. , 1999, Contraception.

[20]  I. Fraser,et al.  A comparative study of two contraceptive vaginal rings releasing norethindrone acetate and differing doses of ethinyl estradiol. , 1999, Contraception.

[21]  B J Oddens,et al.  Women's satisfaction with birth control: a population survey of physical and psychological effects of oral contraceptives, intrauterine devices, condoms, natural family planning, and sterilization among 1466 women. , 1999, Contraception.

[22]  D. Serfaty,et al.  A comparison of the cycle control and tolerability of two ultra low-dose oral contraceptives containing 20 micrograms ethinylestradiol and either 150 micrograms desogestrel or 75 micrograms gestodene. , 1998, The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception.

[23]  M. Rosenberg,et al.  Weight change with oral contraceptive use and during the menstrual cycle. Results of daily measurements. , 1998, Contraception.

[24]  L. Bahamondes,et al.  Efficacy and acceptability of two monophasic oral contraceptives containing ethinylestradiol and either desogestrel or gestodene. , 1998, The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception.

[25]  H. Kuhl,et al.  A randomized cross-over study on various hormonal parameters of two triphasic oral contraceptives. , 1998, Contraception.

[26]  J. Endrikat,et al.  A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 micrograms ethinylestradiol/75 micrograms gestodene and 30 micrograms ethinylestradiol/75 micrograms gestodene, with respect to efficacy, cycle control, and tolerance. , 1995, Contraception.

[27]  P. Harrison,et al.  Contraceptive research and development: looking to the future. , 1997 .

[28]  U. Beisiegel,et al.  Investigation of the influence of two low-dose monophasic oral contraceptives containing 20 micrograms ethinylestradiol/75 micrograms gestodene and 30 micrograms ethinylestradiol/75 micrograms gestodene, on lipid metabolism in an open randomized trial. , 1996, Contraception.

[29]  W. Feichtinger,et al.  Shorter pill-free interval in combined oral contraceptives decreases follicular development. , 1996, Contraception.

[30]  G. Borm,et al.  Changes in androgens during treatment with four low-dose contraceptives. , 1996, Contraception.

[31]  J. Endrikat,et al.  A comparative study of the effects of the hemostatic system of two monophasic gestodene oral contraceptives containing 20 μg and 30 μg ethinylestradiol , 1996 .

[32]  J. Endrikat,et al.  A comparative study of the effects of the hemostatic system of two monophasic gestodene oral contraceptives containing 20 micrograms and 30 micrograms ethinylestradiol. , 1996, Contraception.

[33]  E. Kustra,et al.  The influence of the dose of ethinylestradiol in oral contraceptives on follicle growth. , 1995, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[34]  H. Bennink,et al.  Ovarian activity suppression by two different low-dose triphasic oral contraceptives. , 1995, Contraception.

[35]  I. Wiegratz,et al.  Effect of two oral contraceptives containing ethinylestradiol and gestodene or norgestimate upon androgen parameters and serum binding proteins. , 1995, Contraception.

[36]  J. Foidart,et al.  Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. , 1995, The Journal of clinical endocrinology and metabolism.

[37]  M. Rosenberg,et al.  Use and misuse of oral contraceptives: risk indicators for poor pill taking and discontinuation. , 1995, Contraception.

[38]  S. Koetsawang,et al.  Multicenter trial of two monophasic oral contraceptives containing 30 mcg ethinylestradiol and either desogestrel or gestodene in Thai women. , 1995, Contraception.

[39]  M. Franchini,et al.  Evaluation of body composition during low-dose estrogen oral contraceptives treatment. , 1995, Acta Europaea fertilitatis.

[40]  R. Ge,et al.  A multicentred phase III comparative clinical trial of Mesigyna, Cyclofem and Injectable No. 1 given monthly by intramuscular injection to Chinese women. I. Contraceptive efficacy and sid effects. , 1995, Contraception.

[41]  R. J. Hayes,et al.  Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. , 1995, JAMA.

[42]  R. Turner.  Most British Women Use Reliable Contraceptive Methods, but Many Fear Health Risks from Use , 1994 .

[43]  P. Fioretti,et al.  Clinical comparison of two low-dose oral contraceptives, Minulet and Mercilon, in women over 30 years of age. , 1994, Contraception.

[44]  J. Paulsen,et al.  Effect of norethisterone and levonorgestrel in low‐dose multiphasic oral contraceptives on serum lipids , 1993, Acta obstetricia et gynecologica Scandinavica.

[45]  D. Hellberg,et al.  Long-interval treatment regimen with a desogestrel-containing oral contraceptive. , 1993, Contraception.

[46]  J. Schnitker,et al.  The influence of different modern low-dose oral contraceptives on intermenstrual bleeding. , 1991 .

[47]  N. Loudon,et al.  A double-blind comparison of the efficacy and acceptability of Femodene and Microgynon-30. , 1990, European journal of obstetrics, gynecology, and reproductive biology.

[48]  G. Hoppe,et al.  A study comparing a gestoden triphasic formulation with a fixed combination OC , 1989, Advances in contraception : the official journal of the Society for the Advancement of Contraception.

[49]  E. Woods,et al.  Adolescents' compliance with the use of oral contraceptives. , 1987, JAMA.

[50]  R. Lammintausta,et al.  Plasma renin activity, blood pressure and body weight during two years' oral contraception with two different low-estrogen combinations. , 1987, Annales chirurgiae et gynaecologiae. Supplementum.

[51]  U. Lachnit-Fixson,et al.  Clinical comparison between a monophasic preparation and a triphasic preparation , 1984 .

[52]  K. White,et al.  Clinical epidemiology. , 1983, International journal of epidemiology.

[53]  S. Srivannaboon,et al.  Comparative clinical trial of two oral contraceptives with a low--estrogen content. , 1977, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.

[54]  F. Vickerson,et al.  A double-blind comparison of two oral contraceptives containing 50 mu g. and 30 mu g. ethinyl estradiol. , 1974, Current therapeutic research, clinical and experimental.

[55]  J. Goldzieher,et al.  A placebo-controlled double-blind crossover investigation of the side effects attributed to oral contraceptives. , 1971, Fertility and sterility.

[56]  W. Spellacy,et al.  The development of elevated blood pressure while using oral contraceptives: a preliminary report of a prospective study. , 1970, Fertility and sterility.